The majority of biomedical innovation right now is coming from the emerging biotech and emerging biopharma (EBP) industry. EBPs now represent 65% of the total drug development pipeline globally with an additional 7% being developed by EBPs in partnership with larger firms. Below are some key trends that EBPs should keep an eye out for in 2023.